Sammut, Stephen-John http://orcid.org/0000-0003-4472-904X
Galson, Jacob D.
Minter, Ralph
Sun, Bo http://orcid.org/0000-0002-5507-6657
Chin, Suet-Feung http://orcid.org/0000-0001-5697-1082
De Mattos-Arruda, Leticia http://orcid.org/0000-0002-4992-3645
Finch, Donna K.
Schätzle, Sebastian
Dias, Jorge
Rueda, Oscar M.
Seoane, Joan http://orcid.org/0000-0002-6541-5974
Osbourn, Jane
Caldas, Carlos http://orcid.org/0000-0003-3547-1489
Bashford-Rogers, Rachael J. M. http://orcid.org/0000-0002-6838-0711
Article History
Received: 20 February 2024
Accepted: 15 March 2024
First Online: 2 May 2024
Competing interests
: R.J.M.B.-R. is a cofounder of Alchemab Therapeutics and consultant for Alchemab Therapeutics, GSK, Roche, EnaraBio and UCB. S.S., J.D., J.O., R.M., D.K.F. and J.D.G. are, or were, employed by Alchemab Therapeutics. J.S. is a cofounder of Mosaic Biomedicals and has ownership interests in Mosaic Biomedicals and Northern Biologics. J.S. received grant/research support from Mosaic Biomedicals, Northern Biologics, Roche/Glycart, Hoffmann-La Roche and AstraZeneca. The other authors declare no competing interests.